Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Fc-Gamma Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Receptors belonging to the immunoglobulin superfamily that bind to the Fc portion of IgG molecules and play a role in the phagocytosis of opsonized bacteria.
Non-immunostimulatory antibody and compositions containing the same
ActiveUS20070148167A1Immunoglobulins against animals/humansEnzymologyTherapeutic antibodyFc-Gamma Receptor
The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B / C loop, FcRn binding domain, and the F / G loop. The antibody of the invention is useful in the preparation of therapeutic antibodies and pharmaceutical compositions and kits containing the same.
Owner:MERCK SHARP & DOHME CORP
MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
InactiveUS20130149300A1Good curative effectLow toxicitySugar derivativesImmunoglobulins against cytokines/lymphokines/interferonsDiseaseFc-Gamma Receptor
Disclosed herein are GNGN and G1 / G2 antibodies that recognize and bind various FcRs and C1q. Also disclosed herein are glycan-optiminzed antibodies, predominantly of the GNGN or G1 / G2 glycoform, with enhanced Fcγ receptor binding achieved through CHO, Nicotiana benthamiana and yeast manufacturing systems. Nucleic acids encoding these antibodies, as well as expression vectors and host cells including these nucleic acids are also disclosed herein. Methods and pharmaceutical compositions including the monoclonal antibodies are provided herein for the prevention and / or therapeutic treatment of viral infections, cancers and inflammatory diseases.
Owner:MAPP BIOPHARM +1
Modulation of Fc gamma receptors for optimizing immunotherapy
InactiveUS20060193857A1Promote maturityInhibition of maturationArtificial cell constructsAntibody ingredientsAutoimmune conditionDendritic cell
The present invention relates to methods for modulating the maturation of dendritic cells. In particular, the invention provides methods for (a) promoting the maturation of dendritic cells thereby producing mature dendritic cells, and (b) preventing the maturation of dendritic cells thereby preventing maturation and producing tolerogenic dendritic cells. The present invention further relates to methods for treating autoimmune diseases with tolerogenic dendritic cells produced by methods of the invention. The present invention also relates to methods for treating cancer, neoplastic diseases, and infectious diseases with mature dendritic cells produced by methods of the present invention. The invention moreover relates to kits that provide the materials for conducting the methods of the invention.
Owner:SLOAN KETTERING INST FOR CANCER RES
Chimeric Fc-gamma Receptor and Method for Determination of ADCC Activity by Using the Receptor
An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors.To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse FcγR3 or mouse FcγR4 with the transmembrane domain / intracellular domain of human γ chain or human FcγR3, and expressed the chimeric molecules in human NK92 cells. It was revealed that the ADCC activity can be induced by the chimeric receptors produced by any combination of the domains, and that the ADCC activity of mouse antibodies can be measured using the chimeric receptors of the present invention.
Owner:CHUGAI PHARMA CO LTD
Non-immunostimulatory antibody and compositions containing the same
ActiveUS7700099B2Immunoglobulins against animals/humansEnzymologyTherapeutic antibodyFc-Gamma Receptor
Owner:MERCK SHARP & DOHME CORP
Fc gamma receptor-binding polypeptide variants and methods related thereto
InactiveUS20100203046A1Improve performanceIncrease free energySugar derivativesAntibody ingredientsFc-Gamma ReceptorDrug biological activity
Owner:BIOGEN MA INC
Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
InactiveUS20060165653A1Improve abilitiesPeptide/protein ingredientsMicrobiological testing/measurementFc(alpha) receptorFc-Gamma Receptor
Methods for the use of Fc gamma receptor (FcγR) polymorphisms as a diagnostic for intervention with interleukin-2 (IL-2) immunotherapy are provided. The methods comprise detecting the allelic pattern of an FcγRIIIA gene or FcγRIIA gene of an individual, and determining whether the allelic pattern is predictive of a positive therapeutic response to IL-2 immunotherapy. The presence of the FcγRIIIA 158F / F homozygous genotype, and / or the presence of one or both copies of the FcγRIIIA 48L allele, and / or the presence of one or both copies of the FcγRIIA 131R allele is predictive of a positive therapeutic response to IL-2 immunotherapy, and therefore indicative of medical intervention with IL-2 immunotherapy for treatment of an immune disorder. The diagnostic method finds use in identifying those individuals whose immune function can be improved by treatment with IL-2 immunotherapy, particularly for individuals with cancer.
Owner:CHIRON CORP
Molecules with antigen binding and polyvalent FC gamma receptor binding activity
ActiveUS9683044B2Potent antibody-mediated cell cytoxicityPotent complement-dependent cell cytoxicity and direct cytotoxicityAntibacterial agentsSenses disorderFc receptorDisease
The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.
Owner:GLIKNIK
Modified Fc fragment, antibody comprising same, and use thereof
ActiveCN110914296AAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsFc-Gamma ReceptorAntiendomysial antibodies
Owner:WUHAN YZY BIOPHARMA CO LTD
Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
InactiveUS20190135925A1Efficiently depletedAdd featureHybrid immunoglobulinsAntibody mimetics/scaffoldsFc receptorRegulatory T cell
The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyR11b (CD32b).
Owner:CANCER RES TECH LTD
Anti-cd16 binding molecules
The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc Gamma RIIIA), and in particular binding molecules that specifically bind the A form Fc Gamma RIII but do not bind to the B form of Fc Gamma RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
Owner:AFFIMED GMBH
Monoclonal antibodies against dengue and other viruses with deletion in fc region
Owner:THE U S AS REPRESENTED BY THE SEC DEPT OF HEALTH & HUMAN SERVICES
Monoclonal antibodies against dengue and other viruses with deletion in Fc region
The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.
Owner:UNITED STATES OF AMERICA
Heavy chain constant regions with reduced binding to Fc gamma receptors
ActiveUS10556952B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody SuppressionGlycine
The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and / or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
Owner:REGENERON PHARM INC
Determination of Interactions of Constant Parts of Antibodies with FC-Gamma Receptors
InactiveUS20120070819A1Antibody mimetics/scaffoldsMicrobiological testing/measurementFc-Gamma ReceptorBiological activation
The invention relates to a novel method for the exact determination of the binding of the Fc-part of IgG-antibodies to Fc-gamma receptors, and for the simultaneous examination of the antigen-specificity and the Fc-gamma-receptor activation, as well as specific materials for use in said method. The invention furthermore relates to a method for identifying substances that affect the binding of the Fc-part of IgG-antibodies to Fc-gamma receptors, on the basis of the method for the exact determination of the binding of the Fc-part.
Owner:PAUL EHRLICH INST BUNDESAMT FUR SERA & IMPFSTOFFE
Transgenic non-human animal expressing human-specific molecules and human FC gamma RECEPTOR FAMILY
ActiveCN107529739AHigh sensitivityImmunoglobulin superfamilyMicrobiological testing/measurementHuman animalFc-Gamma Receptor
Owner:INST OF IMMUNOLOGY +1
Chimeric antigen receptor comprising Fcgamma RI and application thereof
ActiveCN110204619APolypeptide with localisation/targeting motifMammal material medical ingredientsAntigenFc-Gamma Receptor
The present disclosure relates to the field of biomedicine, and in particular to a chimeric antigen receptor comprising an Fcgamma receptor I and uses thereof. The chimeric antigen receptor comprisesA) a Fc gamma receptor I extracellular domain, B) a hinge region, C) a transmembrane domain, and D) an intracellular signaling domain. The chimeric antigen receptor can improve the therapeutic effectof antibody drugs through the ADCC effect.
Owner:REGENECORE BIOTECH CO LTD
Antigen-binding molecule for promoting loss of antigens
The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fc-gamma-receptor-binding structure domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fc gamma receptor-binding domain has higher binding activity to the Fc gamma receptor in a neutral pH range condition than an Fc gamma region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain.
Owner:CHUGAI PHARMA CO LTD
Treatment strategies for immune-response disorders by using Fc receptor polymorphisms as diagnostics
The present invention provides diagnostic methods utilizing Fc gamma receptor (Fc gamma R) polymorphisms as interleukin-2 (IL-2) immunotherapeutic intervention. The method includes detecting the allelic pattern of the FcγRIIIA gene or the FcγRIIA gene in an individual and determining whether the allelic pattern predicts a positive therapeutic response to IL-2 immunotherapy. Presence of FcγRIIIA 158F / F homozygous genotype, and / or presence of one or two copies of FcγRIIIA 48L allele, and / or presence of one or two copies of FcγRIIA 131RL allele predicts immunity to IL-2 The treatment had a positive therapeutic response, thus suggesting that IL-2 immunotherapy can be used as a medical intervention for the treatment of immune diseases. The diagnostic method can be used to identify individuals, especially those with cancer, who can improve their immune function through IL-2 immunotherapy.
Owner:CHIRON CORP
Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors
ActiveUS20180282411A1Reduce the binding forceImmunoglobulins against cell receptors/antigens/surface-determinantsGlycineFc-Gamma Receptor
The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and / or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
Owner:REGENERON PHARM INC
Heteromultimers with reduced or silenced effector function
InactiveCN105849129AReduce the binding forceNervous disorderAntipyreticFc-Gamma ReceptorHinge region
Provided herein are heteromultimer constructs with reduced or silenced effector function. In an embodiment is provided a heteromultimer construct comprising an IgG Fc construct having a first and a second Fc polypeptide, each Fc polypeptide comprising a modified lower hinge region wherein: the modified lower hinge region of said first Fc polypeptide comprises at least one amino acid modification, the modified lower hinge region of said second Fc polypeptide comprises at least one amino acid modification which is different from at least one amino acid modification of said first Fc polypeptide, and the IgG Fc construct displays reduced binding to all Fc Gamma receptors and to C1q protein as compared to a corresponding parent IgG Fc construct. Also provided are methods of producing such heteromultimer constructs, and methods of reducing ADCC for an antibody construct by reducing effector function.
Owner:ZHENHUO BIOPHARMACEUTICAL CO LTD
Method for treating autoimmune diseases and compositions therefor
ActiveUS20070207128A1Ameliorate any conditionTreating or ameliorating an autoimmune diseaseBiocideImmunoglobulins against animals/humansFc-Gamma ReceptorAutoimmune condition
A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and / or dendritic cells to interrupt autoimmunity in a host. The method provides a Fcγ receptor-specific complex or a complex which results in the co-crosslinking of Fcγ-chains for treating the leukocytes and / or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fcγ receptor-specific complex and / or complex which results in the co-crosslinking of Fcγ-chains is used to treat a biological sample comprising leukocytes and / or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.
Owner:CANADIAN BLOOD SERVICES
Novel combination and use of antibodies
PendingCN111683969AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsImmunopotencyFc-Gamma Receptor
Described is the use of a first antibody molecule that specifically binds Fc gamma Rllb via its Fab region, but lacks Fc region or has reduced binding to Fc gamma receptors via its Fc region, for usein combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc gamma receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and / or deactivation of the immune cell in the treatment of an Fc gamma Rllb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.
Owner:BIOINVENT INT AB +1
Soluble hybrid fcgamma receptors and related methods
ActiveUS20140107034A1Reduce inflammationReduced responsePeptide/protein ingredientsAntipyreticFc-Gamma ReceptorImmune complex
Owner:ZYMOGENETICS INC
Chimeric antigen receptor comprising FcγRI and its application
ActiveCN110204619BPolypeptide with localisation/targeting motifMammal material medical ingredientsFc-Gamma ReceptorAntiendomysial antibodies
The present disclosure relates to the field of biomedicine, and in particular to a chimeric antigen receptor comprising an Fcgamma receptor I and uses thereof. The chimeric antigen receptor comprisesA) a Fc gamma receptor I extracellular domain, B) a hinge region, C) a transmembrane domain, and D) an intracellular signaling domain. The chimeric antigen receptor can improve the therapeutic effectof antibody drugs through the ADCC effect.
Owner:REGENECORE BIOTECH CO LTD
T cell expressing an fc gamma receptor and methods of use thereof
PendingUS20210401893A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyFc receptorFc-Gamma Receptor
A T cell expressing an FC gamma receptor is provided. Accordingly there is provided a T cell genetically engineered to express a first polypeptide comprising an amino acid sequence of an Fc receptor common γ chain (FcRγ), said amino acid sequence is capable of transmitting an activating signal; and a second polypeptide comprising an extracellular ligand-binding domain of an Fcγ receptor capable of binding an Fc ligand and an amino acid sequence capable of recruiting said first polypeptide such that upon binding of said Fc ligand to said extracellular ligand-binding domain of said Fcγ receptor said activating signal is transmitted.
Owner:RAMOT AT TEL AVIV UNIV LTD
Modified Fc gamma receptor type III (FCγIII, HNA-1) polypeptides and the uses thereof
ActiveUS10571468B2Decrease non-specific reactivityIncreases specific reactivityDepsipeptidesPeptide preparation methodsFc-Gamma ReceptorAntiendomysial antibodies
The invention is directed to engineered Fc gamma receptor type III (Fcγ111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).
Owner:ONE LAMBDA INC
Compositions and methods for enhancement of immune responses
ActiveUS11266728B2Improving immunogenicityGood curative effectSsRNA viruses positive-senseTumor rejection antigen precursorsFc-Gamma ReceptorPharmaceutical drug
Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating the antigen with an antagonist of an Fc gamma receptor to form an antigen fusion protein. Also provided is a method of enhancing an immune response to an antigen in a subject, including administering to the subject an effective amount of an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. The present invention may be applied in the development of potent vaccines based on targeting vaccine antigens to antigen-presenting cells via binding to Fc gamma receptors.
Owner:NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
Anti cd25 FC gamma receptor bispecific antibodies for tumor specific cell depletion
PendingCN109476739AHybrid immunoglobulinsAntibody mimetics/scaffoldsFc(alpha) receptorRegulatory T cell
The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).
Owner:CANCER RES TECH LTD
Agents that interfere with thymic stromal lymphopoietin (TSLP) receptor signaling
PendingCN114401741AImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntigenDisease
Owner:TAVOTEK BIOTHERAPEUTICS (HONG KONG) LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com